Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy - Scorecard - MDSpire

Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy

  • By

  • Hardeep Singh Kalsi

  • Kristofer Linton-Reid

  • Changhyun Kim

  • Mitchell Chen

  • Victoria Crowe

  • Esubalew Alemu

  • Samir Mahboobani

  • David Gibeon

  • Alexander Procter

  • Mohsen Hajhosseiny

  • Cara Owens

  • Emily C. Bartlett

  • Nuria Porta

  • Thesha Thavaraja

  • Simon Doran

  • Anand Devaraj

  • Bhupinder Sharma

  • Arjun Nair

  • Eric O. Aboagye

  • Richard W. Lee

  • May 6, 2026

  • 0 min

Share

Clinical Scorecard: Differentiation Model Utilizing Semantic CT Features: Distinguishing New Primary Lung Cancer from Metastatic Disease Following Prior Malignancies

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationCancer survivors with new lung nodules/lesions after prior malignancies
Care Setting

Key Highlights

  • Structured reporting improves diagnostic accuracy and reduces variability.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular imaging follow-ups every 3-6 months to assess lesion characteristics and changes over time.

      Risks

        Patient & Prescribing Data

        Management strategies differ significantly between new lung cancer and metastasis, e.g., chemotherapy for lung cancer vs. targeted therapy for metastasis.

        Clinical Best Practices

        • Ensure continuous education on reader variability and its impact on diagnosis.

        References

        Original Source(s)

        Semantic CT features and differentiation model: new primary lung cancer versus metastasis after previous malignancy

        • by Hardeep Singh Kalsi, Kristofer Linton-Reid, Changhyun Kim, Mitchell Chen, Victoria Crowe, Esubalew Alemu, Samir Mahboobani, David Gibeon, Alexander Procter, Mohsen Hajhosseiny, Cara Owens, Emily C. Bartlett, Nuria Porta, Thesha Thavaraja, Simon Doran, Anand Devaraj, Bhupinder Sharma, Arjun Nair, Eric O. Aboagye, Richard W. Lee

        • May 6, 2026

        Related Content

        Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry

        Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

        Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation